 | | Vol. 14.11 – 24 March, 2022 |
| |
|
|
| Scientists produced allogeneic hematopoietic stem cell (HSC)-engineered Invariant natural killer T (iNKT) cells through TCR engineering of human cord blood CD34+ HSC and differentiation of these HSCs into iNKT cells in an ex vivo HSC-Derived iNKT Cell Culture.
[Stem Cell Research & Therapy] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human umbilical cord-derived MSCs infusions improved systemic metabolic homeostasis and alleviated insulin resistance in epididymal adipose tissue but elicited no change in weight.
[Stem Cell Research & Therapy] |
|
|
|
| To distinguish responses related to viral infection vs. recognition, the authors evaluated cotyledons perfused with either active or inactivated Zika virus (ZIKV).
[Communications Biology] |
|
|
|
| Researchers grew human Wharton’s jelly MSCs (hWJ-MSCs) on a striped micropattern containing spider silk protein from Argiope appensa, aiming to direct hWJ-MSCs chondrogenesis using micropattern made of spidroin bioink as opposed to fibronectin that was often used as the gold standard.
[Scientific Reports] |
|
|
|
| PCR, bulk RNA sequencing, immunohistochemistry, and immunofluorescence for renalase and its binding partners, PMCA4b and PZP, were performed on human placental tissue from second-trimester and full-term placentas separated into decidua, placental villi and chorionic plates.
[Scientific Reports] |
|
|
|
| Scientists observed tumor formation in NOD SCID mice after a single subcutaneous injection of human umbilical cord-MSCs and the effect of these cells on tumor growth in tumor-bearing mice.
[BMC Cancer] |
|
|
|
| Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant non-small cell lung cancer.
[Cell Reports Medicine] |
|
 |
|
|
|
| The author covers recent developments in our understanding of the risks of SARS-CoV-2 infection in pregnancy, and how vaccination can reduce these.
[Nature Reviews Immunology] |
|
|
|
| Growth factors, cytokines, chemokines, extracellular matrix components, and metabolic products were all found to be functional molecules of MSCs in various therapeutic paradigms.
[Signal Transduction and Targeted Therapy] |
|
|
|
|
| IMAC Holdings, Inc. announced it has initiated the third and final cohort of its Phase I clinical trial for its investigational compound utilizing umbilical cord-derived allogenic MSCs for the treatment of bradykinesia due to Parkinson’s disease.
[IMAC Holdings, Inc.] |
|
|
|
|
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Mayo Clinic – Jacksonville, Florida, United States |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | Aspect Biosystems – Vancouver, British Columbia, Canada |
|
|
|
| | Singapore-MIT Alliance for Research and Technology (SMART) Centre – Singapore, Singapore |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
